• Explore /
  • Poster
  • / Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.

Post hoc pooled analysis of first-line (1L) pembrolizumab (pembro) for advanced urothelial carcinoma (UC): Outcomes by response at week nine in KEYNOTE-052 and KEYNOTE-361.

Abstract Video & Slides Poster

Authors

null

Thomas Powles

Barts Cancer Institute, Queen Mary University of London, London, United Kingdom

Thomas Powles , Ajjai Shivaram Alva , Mustafa Ozguroglu , Peter H. O'Donnell , Yohann Loriot , Tibor Csoszi , Jacqueline Vuky , Rafael Morales-Barrera , Elizabeth R. Plimack , Nobuaki Matsubara , Yves Fradet , Lajos Geczi , Seyda Gunduz , Ronac Mamtani , Dean F. Bajorin , Chih-Chin Liu , Kentaro Imai , Blanca Homet Moreno , Joaquim Bellmunt , Arjun Vasant Balar

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Urothelial Carcinoma

Track

Urothelial Carcinoma

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02335424 and NCT02853305

Citation

J Clin Oncol 40, 2022 (suppl 6; abstr 519)

DOI

10.1200/JCO.2022.40.6_suppl.519

Abstract #

519

Poster Bd #

G7

Abstract Disclosures

Similar Posters

First Author: Thomas Powles

First Author: Ozgur Ozyilkan

First Author: Benjamin Miron

First Author: Inkeun Park